Assembly Biosciences reports positive interim results for ABI-5366 in Phase 1b genital herpes study
Reuters
Nov 11, 2025
Assembly Biosciences reports positive interim results for ABI-5366 in Phase 1b genital herpes study
Assembly Biosciences Inc. reported cash, cash equivalents, and marketable securities of $232.6 million as of September 30, 2025, up from $75.0 million at June 30, 2025, following $175 million in gross proceeds from equity financings. Revenue from collaborative research with Gilead was $10.8 million for the third quarter of 2025, compared to $6.8 million for the same period in 2024. Research and development expenses increased to $16.6 million from $13.5 million year over year, mainly due to higher spending on the HSV program. General and administrative expenses were $5.1 million, up from $4.3 million in the previous year, reflecting higher professional fees and increased stock-based compensation. The company released positive interim results for its ABI-5366 and ABI-6250 candidates and anticipates additional data readouts from its HSV program by year-end. Initiation of a Phase 2 study for ABI-5366 is expected in mid-2026. Assembly Biosciences projects its current cash position will fund operations into late 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assembly Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572530-en) on November 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.